- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | H.C. Wainwright bestätigt Kaufempfehlung für Reviva, senkt aber Kursziel nach FDA-Feedback | 13 | Investing.com Deutsch | ||
| Mi | Reviva Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright | 1 | Investing.com | ||
| Di | FDA fordert weitere Studie: Aktie von Reviva Pharmaceuticals bricht ein | 21 | Investing.com Deutsch | ||
| REVIVA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Di | FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug | 4 | Benzinga.com | ||
| Di | FDA fordert zweite Phase-3-Studie für Schizophrenie-Medikament von Reviva | 4 | Investing.com Deutsch | ||
| Di | FDA recommends second phase 3 trial for Reviva's schizophrenia drug | 2 | Investing.com | ||
| Di | Reviva Pharmaceuticals: Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia | 191 | GlobeNewswire (Europe) | Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the... ► Artikel lesen | |
| Di | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.12. | NSE - REVIVA PHARMACEUTICALS HOLDINGS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 6 | SEC Filings | ||
| 13.11. | Reviva Pharmaceuticals: Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 1.064 | GlobeNewswire (Europe) | - Pre-NDA meeting with FDA to discuss brilaroxazine's path to approval for schizophrenia planned in Q4 2025 - - Potential NDA submission for schizophrenia indication targeted for Q2 2026 - - European... ► Artikel lesen | |
| 13.11. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 13.11. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 28.10. | Reviva to present brilaroxazine schizophrenia data at CNS Summit | 4 | Investing.com | ||
| 28.10. | Reviva Pharmaceuticals: Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025 | 4 | GlobeNewswire (USA) | ||
| 27.10. | H.C. Wainwright slashes Reviva Pharmaceuticals stock price target on dilution concerns | 7 | Investing.com | ||
| 17.10. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 6 | SEC Filings | ||
| 14.10. | Birla Cellulose launches Liva Reviva M, pioneering circular fashion | 2 | fibre2fashion | ||
| 26.09. | Reviva Pharmaceuticals senkt Präsenzquorum für Hauptversammlungen | 18 | Investing.com Deutsch | ||
| 19.09. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 13 | SEC Filings | ||
| 19.09. | Reviva Pharmaceuticals stock plunges after pricing $9 million offering | 1 | Investing.com |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 35,940 | +1,37 % | Bayer, Rheinmetall SAP - was ist noch drin? | Für 2026 treffen bei deutschen Aktien hohe Erwartungen auf hohe Bewertungen. Auf fallende Kurse setzen - sprich short gehen - bleibt aber kompliziert in Sachen Timing. Denn wer in den vergangenen 15... ► Artikel lesen | |
| NOVO NORDISK | 44,425 | +8,53 % | Börsenfrühstück: Baidu, Novo Nordisk & DroneShield mit frischen Impulsen | Marktbericht für den 22. Dezember 2025: An den internationalen Märkten zeigt sich zum Wochenauftakt ein ähnliches Bild wie in Europa: Stabilisierung ja, Euphorie nein. In den USA hatten die großen Indizes... ► Artikel lesen | |
| ROCHE | 352,50 | +1,50 % | Roche-Chef erwartet Erhöhung der Medikamentenpreise | Bern - Roche-Chef Thomas Schinecker hat in einem Interview Druck zur Preiserhöhung neuer Medikamente in der Schweiz gemacht. Der Chef des Pharmakonzerns zeigte die Konsequenzen auf, sollte die Schweiz... ► Artikel lesen | |
| VIATRIS | 10,090 | -0,15 % | Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln | NEW DELHI (dpa-AFX) - Viatris Inc. (VTRS) announced that it has entered into definitive agreements with Biocon Limited for the sale of its equity stake in Biocon Biologics Limited. Under the... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 6,475 | -0,46 % | President Trump Just Reclassified Marijuana. Are Green Thumb, Tilray, and Trulieve Stocks No-Brainer Buys? | ||
| TONIX PHARMACEUTICALS | 14,100 | -2,76 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University | Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain Compelling safety and pharmacokinetic profiles in animals support IND-enabling... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 25,600 | +5,13 % | Newron Pharmaceuticals S.p.A.: Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week | Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral... ► Artikel lesen | |
| CASSAVA SCIENCES | 1,981 | +8,55 % | Cassava Sciences, Inc.: Cassava Announces Agreement to Settle Securities Class Action Litigation | AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 2,482 | +1,31 % | Oramed Pharmaceuticals Inc.: Oramed Reports Fiscal Third Quarter 2025 Financial Results | Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million
NEW YORK, Nov. 17, 2025 /PRNewswire/ --... ► Artikel lesen | |
| COMPASS PATHWAYS | 5,350 | 0,00 % | Why COMPASS Pathways plc (CMPS) Draws Both Optimism and Caution | ||
| ACHIEVE LIFE SCIENCES | 3,730 | +3,32 % | Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program | One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner's National Priority Voucher for E-cigarette or Vaping CessationConference Call Scheduled for 8:30 AM EST Today, November 6, 2025... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 13,700 | -0,83 % | Wachstumssorgen: Leerink Partners stuft Aurinia Pharmaceuticals herab | ||
| OPUS GENETICS | 1,688 | -1,75 % | Opus Genetics, Inc.: Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease | RESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 7,570 | -5,38 % | Kazia Therapeutics Limited: Kazia Therapeutics Regains Full Nasdaq Listing Compliance | Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength
SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,120 | -0,83 % | Allergy Therapeutics - Grassmuno marketing authorisation in Germany |
REVIVA PHARMACEUTICALS HOLDINGS INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,305 Euro und damit +9,71 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVA PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.